LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $77.57.

LMAT has been the topic of a number of analyst reports. Roth Mkm restated a “buy” rating and set a $100.00 target price on shares of LeMaitre Vascular in a research note on Friday, May 31st. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price objective for the company from $59.00 to $75.00 in a research report on Friday, April 26th. Barrington Research upped their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. JMP Securities lifted their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Finally, Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $87.97 on Friday. LeMaitre Vascular has a one year low of $44.27 and a one year high of $91.76. The business has a fifty day moving average of $82.32 and a 200 day moving average of $71.26. The firm has a market capitalization of $1.97 billion, a P/E ratio of 58.26, a PEG ratio of 2.62 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. The firm had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.27 EPS. Analysts expect that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 8,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 127,437 shares of company stock worth $10,076,242. Insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Kings Path Partners LLC purchased a new stake in LeMaitre Vascular in the 2nd quarter valued at about $1,694,000. Ausbil Investment Management Ltd raised its stake in shares of LeMaitre Vascular by 145.7% during the second quarter. Ausbil Investment Management Ltd now owns 35,986 shares of the medical instruments supplier’s stock valued at $2,961,000 after acquiring an additional 21,341 shares in the last quarter. F M Investments LLC bought a new stake in shares of LeMaitre Vascular during the second quarter valued at approximately $7,443,000. Conestoga Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 0.4% in the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier’s stock valued at $159,747,000 after purchasing an additional 8,584 shares during the period. Finally, Legato Capital Management LLC increased its holdings in LeMaitre Vascular by 31.2% during the 2nd quarter. Legato Capital Management LLC now owns 25,336 shares of the medical instruments supplier’s stock worth $2,085,000 after purchasing an additional 6,028 shares during the period. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.